Belantamab Mafodotin-Blmf

Phase 3Antibody–drug conjugate

Novo Nordisk

Belantamab Mafodotin-Blmf is one of 81 small molecule programs targeting Multiple Myeloma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Multiple MyelomaUnknown status

ObesityRecruiting

Multiple MyelomaPhase 2

Unknown status

ObesityPhase 3

Recruiting

Competition

Competitive Landscape

282 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

Fludara

Sanofi

Phase 3

47 2

Ninlaro

Takeda

Phase 3

18 3

Venclexta

AbbVie

Phase 3

17 4

Biaxin

AbbVie

Phase 3

15 5

Xpovio

KKaryopharm Therapeutics Inc

Phase 3

29 6

Treanda

AAzurity Pharmaceuticals

Phase 3

19 7

Elranatamab

Pfizer

Phase 3

27 8

Mozobil

GGenzyme, a Sanofi Company

Phase 3

15 9

Busulfex

Mezigdomide

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1/2Not yet recruiting

Multiple Myeloma

NCT05581875

Q3 2027

Phase 3Recruiting

Obesity

NCT05573802

Clinical

Trials by Indication[1]

Multiple Myeloma2 trials

A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory

Not yet recruiting·HHellenic Society of Hematology·Phase 1/2·NCT05581875·48 enrolled

A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible

Unknown status·HHellenic Society of Hematology·Phase 1/2·NCT05280275·36 enrolled

Obesity1 trial

ANDES: Cagrilintide + Semaglutide in Obesity

Recruiting· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT05573802·3,000 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Belantamab Mafodotin-Blmf. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Belantamab Mafodotin-Blmf compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Belantamab Mafodotin-Blmf. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novo Nordisk company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Antibody–drug conjugate[2]
Highest Phase: Phase 3[1]
Company: Novo Nordisk

Belantamab Mafodotin-Blmf

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q3 2027

Trials by Indication[1]

Multiple Myeloma2 trials

Obesity1 trial

References

Drug Info

Quick Facts

Related News